Nassim Usman Sells 3,452 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Director Nassim Usman sold 3,452 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $12.00, for a total value of $41,424.00. Following the completion of the sale, the director now directly owns 1,636 shares of the company’s stock, valued at $19,632. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Nassim Usman also recently made the following trade(s):

• On Wednesday, May 1st, Nassim Usman sold 20,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $14.13, for a total value of $282,600.00.

Gyre Therapeutics Stock Up 0.9 %

Shares of GYRE traded up $0.11 during mid-day trading on Monday, hitting $12.04. The company’s stock had a trading volume of 84,645 shares, compared to its average volume of 81,379. The firm has a 50-day simple moving average of $12.86 and a 200 day simple moving average of $16.81. Gyre Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $30.40.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.04 EPS for the quarter. The business had revenue of $27.17 million during the quarter. On average, equities analysts anticipate that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.